Most cited papers from Sunovion (United States)

Sunovion (United States)

What are the most cited papers from Sunovion (United States)?

The most cited paper from Sunovion (United States) is "Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults with Chronic Insomnia" (Andrew D. Krystal, James K. Walsh, EUGENE M. LASKA et al., 2003), with 632 citations. Next come "Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder" (478) and "Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective" (390).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 87 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults with Chronic Insomnia Andrew D. Krystal, James K. Walsh, EUGENE M. LASKA et al. · SLEEP	Oct 2003	632
2	Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder Maurizio Fava, William Vaughn McCall, Andrew D. Krystal et al. · Biological Psychiatry	5 Apr 2006	478
3	Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective Mohamad Shebley et al. · Clinical Pharmacology & Therapeutics Open access	10 Jan 2018	390
4	Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference Min Suk Yang, Charles M. Morin, Kendyl Schaefer et al. · Current Medical Research and Opinion	19 Aug 2009	314
5	Seizure diaries for clinical research and practice: Limitations and future prospects Robert S. Fisher, David E. Blum, Bree D. DiVentura et al. · Epilepsy & Behavior	30 May 2012	314
6	Cyclooxygenase 2‐dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants Medora M. Hardy, Karen Seibert, Pamela Toy Manning et al. · Arthritis & Rheumatism	Jul 2002	303
7	Membrane-Based Affinity Technology for Commercial Scale Purifications Steve A. Brandt, Randal A. Goffe, Stephen B. Kessler et al. · Nature Biotechnology	Jul 1988	299
8	A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia Kenneth S. Koblan, JUSTINE M. KENT, Seth C. Hopkins et al. · New England Journal of Medicine	15 Apr 2020	297
9	Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia Gary K Zammit, Louis J. McNabb, Judy Caron et al. · Current Medical Research and Opinion	24 Nov 2004	295
10	A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms Susan S. D’Souza · Advances in Pharmaceutics Open access	20 Nov 2014	264
11	Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis Thomas J. Struble et al. · Journal of Medicinal Chemistry Open access	3 Apr 2020	263
12	Nightly Treatment of Primary Insomnia With Eszopiclone for Six Months: Effect on Sleep, Quality of Life, and Work Limitations James K. Walsh, Andrew D. Krystal, David A. Amato et al. · SLEEP Open access	Aug 2007	241
13	Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial Richard S.E. Keefe, Kolleen H. Fox, Philip D. Harvey et al. · Schizophrenia Research	15 Nov 2010	239
14	An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia Thomas Röth, Jared P. Walsh, Andrew D. Krystal et al. · Sleep Medicine	18 Oct 2005	230
15	The Economic Burden of Schizophrenia in the United States Aditi P. Kadakia, Maryaline Catillon, Qi Fan et al. · The Journal of Clinical Psychiatry Open access	6 Oct 2022	208
16	A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics Trevor T. Hansel, Sergei A. Kharitonov, Louise Donnelly et al. · The FASEB Journal	8 May 2003	208
17	Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis Michael Joshua Ostacher, Daisy Ng‐Mak, Pankaj Patel et al. · The World Journal of Biological Psychiatry ReviewOpen access	7 Mar 2017	202
18	Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis Celso Arango, Daisy Ng‐Mak, Elaine Finn et al. · European Child & Adolescent Psychiatry ReviewOpen access	22 Nov 2019	199
19	Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients Linda N. Abetz, Krithika Rajagopalan, Polyxane Mertzanis et al. · Health and Quality of Life Outcomes Open access	2011	180
20	SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action Nina Dedic, PHILIP G. JONES, Seth C. Hopkins et al. · Journal of Pharmacology and Experimental Therapeutics Open access	Aug 2019	178
21	Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial Antony D Loebel, Josephine B. Cucchiaro, Kaushik Sarma et al. · Schizophrenia Research Open access	14 Feb 2013	173
22	POSIT: Flexible Shape-Guided Docking For Pose Prediction Brian Kelley, Scott P. Brown, Gregory L. Warren et al. · Journal of Chemical Information and Modeling Open access	7 Jul 2015	166
23	Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models Bohdana Ratitch, Michael O’Kelly, Robert L. Tosiello · Pharmaceutical Statistics	4 Jan 2013	156
24	Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study Henry A. Nasrallah, Robert Silva, Debra L. Phillips et al. · Journal of Psychiatric Research	18 Feb 2013	148
25	Validation of the behavioural activity rating scale (BARS)™: a novel measure of activity in agitated patients Rachel H. Swift, Edmund P. Harrigan, Joseph C. Cappelleri et al. · Journal of Psychiatric Research	Mar 2002	147
26	A 2-Week Efficacy and Safety Study of Eszopiclone in Elderly Patients with Primary Insomnia Martin B. Scharf, Milton K. Erman, Russell P. Rosenberg et al. · SLEEP	Jun 2005	145
27	Eszopiclone in Patients With Insomnia During Perimenopause and Early Postmenopause Cláudio N. Soares, Hadine Joffe, Robert Rubens et al. · Obstetrics and Gynecology	Dec 2006	136
28	A multiphase/extractive enzyme membrane reactor for production of diltiazem chiral intermediate Jorge López, Stephen L. Matson · Journal of Membrane Science	5 Mar 1997	136
29	Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study Melissa P. DelBello, ROBERT S. GOLDMAN, Debra L. Phillips et al. · Journal of the American Academy of Child & Adolescent Psychiatry Open access	14 Oct 2017	133
30	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study C. Warren Olanow, Stewart Alan Factor, Alberto J. Espay et al. · The Lancet Neurology	6 Dec 2019	132
31	ARG1 Is a Novel Bronchodilator Response Gene Augusto A. Litonjua, Jessica Ann Lasky-Su, Kady Schneiter et al. · American Journal of Respiratory and Critical Care Medicine Open access	10 Jul 2008	131
32	The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients Sandra M. Gawchik, Consuelo L. Saccar, Michael James Noonan et al. · Journal of Allergy and Clinical Immunology Open access	Apr 1999	128
33	Viral Vector-Mediated Overexpression of Estrogen Receptor-α in Striatum Enhances the Estradiol-Induced Motor Activity in Female Rats and Estradiol-Modulated GABA Release Kristin N. Schultz, Silke A. von Esenwein, Ming Hu et al. · Journal of Neuroscience Open access	11 Feb 2009	125
34	Properly Designed Modular Asymmetric Synthesis for Enantiopure Sulfinamide Auxiliaries from N-Sulfonyl-1,2,3-oxathiazolidine-2-oxide Agents Zhengxu S. Han, Dhileepkumar Krishnamurthy, Paul T. Grover et al. · Journal of the American Chemical Society	12 Jun 2002	124
35	Long-term safety and tolerability of lurasidone in schizophrenia Leslie Citrome, Josephine B. Cucchiaro, Kaushik Sarma et al. · International Clinical Psychopharmacology	6 Mar 2012	122
36	Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study Antony D Loebel, Josephine B. Cucchiaro, Jane Xu et al. · Schizophrenia Research Open access	17 Apr 2013	118
37	Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study Masaaki Ogasa, Tatsuya Kimura, Mitsutaka Nakamura et al. · Psychopharmacology Open access	18 Aug 2012	116
38	(S)-Albuterol Increases Intracellular Free Calcium by Muscarinic Receptor Activation and a Phospholipase C-Dependent Mechanism in Airway Smooth Muscle SANKAR P. MITRA, Mehmet Can Ugur, Özlem Uğur et al. · Molecular Pharmacology	Mar 1998	116
39	Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III , double‐blind, randomized, placebo‐controlled trial Michael R. Sperling, Bassel W Abou-Khalil, Jay H. Harvey et al. · Epilepsia Open access	22 Dec 2014	114
40	Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease Nancy M. P. King, Laurence M. Melnick, M. Prabu-Jeyabalan et al. · Protein Science Open access	Feb 2002	114
41	Lurasidone for the Treatment of Irritability Associated with Autistic Disorder Antony D Loebel, Matthew N. Brams, ROBERT S. GOLDMAN et al. · Journal of Autism and Developmental Disorders Open access	11 Dec 2015	111
42	Comparison ofR-, S-, andRS-albuterol interaction with human β1 and β2-adrenergic receptors Raymond B. Penn, Thomas Frielle, John R. McCullough et al. · Clinical Reviews in Allergy & Immunology	Mar 1996	111
43	Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine Michelle Kokkinou, Elaine E. Irvine, David R. Bonsall et al. · Molecular Psychiatry Open access	7 May 2020	105
44	Translational aspects of pharmacological research into anxiety disorders: The stress-induced hyperthermia (SIH) paradigm Christiaan H. Vinkers, Meg J.V. van Bogaert, Marianne Klanker et al. · European Journal of Pharmacology	19 Mar 2008	105
45	A practical asymmetric synthesis of (R)-fluoxetine and its major metabolite (R)-norfluoxetine James W. Hilborn, Zhi‐Hui Lu, Alex R. Jürgens et al. · Tetrahedron Letters	Dec 2001	104
46	A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome Russell P. Rosenberg, James M. Roach, Martin B. Scharf et al. · Sleep Medicine	23 May 2007	102
47	Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies Nina Dedic, Heather Dworak, Courtney M. Zeni et al. · International Journal of Molecular Sciences Open access	7 Dec 2021	100
48	Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation Gulshan Sharma, Donald A. Mahler, Valerie M. Mayorga et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation Open access	2017	100
49	A polysomnography study of eszopiclone in elderly patients with insomnia William Vaughn McCall, Milton K. Erman, Andrew D. Krystal et al. · Current Medical Research and Opinion	19 Jul 2006	98
50	Correlates of PLMs variability over multiple nights and impact upon RLS diagnosis Lynn Marie Trotti, Donald L. Bliwise, Sophia A. Greer et al. · Sleep Medicine	4 Dec 2008	98

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.